NO965125L - Heterosykliske forbindelser med tachykininreseptor-antagonistaktivitet, deres fremstilling og anvendelse - Google Patents

Heterosykliske forbindelser med tachykininreseptor-antagonistaktivitet, deres fremstilling og anvendelse

Info

Publication number
NO965125L
NO965125L NO965125A NO965125A NO965125L NO 965125 L NO965125 L NO 965125L NO 965125 A NO965125 A NO 965125A NO 965125 A NO965125 A NO 965125A NO 965125 L NO965125 L NO 965125L
Authority
NO
Norway
Prior art keywords
receptor antagonist
preparation
antagonist activity
tachykinin receptor
heterocyclic compounds
Prior art date
Application number
NO965125A
Other languages
English (en)
Other versions
NO308300B1 (no
NO965125D0 (no
Inventor
Takahide Nishi
Koki Ishibashi
Katsuyoshi Nakajima
Tetsuya Fukazawa
Hitoshi Kurata
Takeshi Yamaguchi
Kazuhiro Ito
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO965125D0 publication Critical patent/NO965125D0/no
Publication of NO965125L publication Critical patent/NO965125L/no
Publication of NO308300B1 publication Critical patent/NO308300B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO965125A 1995-12-01 1996-12-02 Heterosykliske forbindelser med tachykininreseptorantagonistaktivitet, og preparat inneholdende disse NO308300B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP31382895 1995-12-01
JP33636995 1995-12-25
JP29686996 1996-11-08

Publications (3)

Publication Number Publication Date
NO965125D0 NO965125D0 (no) 1996-12-02
NO965125L true NO965125L (no) 1997-06-02
NO308300B1 NO308300B1 (no) 2000-08-28

Family

ID=27338095

Family Applications (1)

Application Number Title Priority Date Filing Date
NO965125A NO308300B1 (no) 1995-12-01 1996-12-02 Heterosykliske forbindelser med tachykininreseptorantagonistaktivitet, og preparat inneholdende disse

Country Status (19)

Country Link
US (2) US6159967A (no)
EP (1) EP0776893B1 (no)
CN (1) CN1142932C (no)
AT (1) ATE213738T1 (no)
AU (1) AU719158B2 (no)
CA (1) CA2191815C (no)
CZ (1) CZ288498B6 (no)
DE (1) DE69619479T2 (no)
DK (1) DK0776893T3 (no)
ES (1) ES2170211T3 (no)
HK (1) HK1011366A1 (no)
HU (1) HU224225B1 (no)
IL (1) IL119729A (no)
MX (1) MX9606082A (no)
NO (1) NO308300B1 (no)
NZ (1) NZ299859A (no)
PT (1) PT776893E (no)
RU (1) RU2135494C1 (no)
TW (1) TW367327B (no)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2135494C1 (ru) * 1995-12-01 1999-08-27 Санкио Компани Лимитед Гетероциклические соединения и композиция на их основе, проявляющая антагонистическое действие в отношении рецепторов тахикинина
PT987269E (pt) 1997-05-30 2003-11-28 Sankyo Co Sais de derivados sulfoxido opticamente activo
WO1999028307A1 (fr) 1997-12-04 1999-06-10 Sankyo Company, Limited Derives heterocycliques alicycliques acyles
AU741924B2 (en) * 1998-01-23 2001-12-13 Sankyo Company Limited Spiropiperidine derivatives
AU1684300A (en) * 1998-12-10 2000-06-26 Sankyo Company Limited Cyclohexylpiperidine derivatives
FR2791346B3 (fr) * 1999-03-25 2001-04-27 Sanofi Sa Nouveaux derives de morpholine, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2796069B3 (fr) * 1999-07-09 2001-08-24 Sanofi Synthelabo Nouveaux procedes de preparation de derives de 2-(2- arylmorpholin-2-yl)ethanol substitues, enantiomeriquement purs, et composes intermediaires utiles dans ces procedes
WO2001029027A1 (fr) * 1999-10-22 2001-04-26 Sankyo Company, Limited Dérivés de 2-alcoxybenzène
JP4907818B2 (ja) 1999-11-03 2012-04-04 エーエムアール テクノロジー インコーポレイテッド アリールおよびヘテロアリール置換テトラヒドロイソキノリン、ならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを阻止するためのそれらの使用
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
RU2301808C2 (ru) 2000-07-11 2007-06-27 Эймр Текнолоджи, Инк. 4-фенилзамещенные тетрагидроизохинолины, фармацевтическая композиция и способ лечения на их основе
FR2824828B1 (fr) * 2001-05-21 2005-05-20 Sanofi Synthelabo Nouveaux derives de piperidinecarboxamide, un procede pour leur preparation et les compositions pharmaceutiques les contenant
JP2004067673A (ja) * 2002-06-11 2004-03-04 Sankyo Co Ltd 環状チオエーテル類の製造法及びその合成中間体
US7396930B2 (en) * 2002-06-11 2008-07-08 Sankyo Company, Limited Process for producing cyclic thioether and synthetic intermediate thereof
EP1533314A4 (en) * 2002-06-11 2006-08-02 Sankyo Co PROCESS FOR THE PREPARATION OF CYCLIC THIOETHERES, AND SYNTHETIC INTERMEDIATE DAF R
MY141736A (en) * 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists
JP2004161757A (ja) * 2002-10-24 2004-06-10 Sankyo Co Ltd 光学活性なスルホキシドの製造法
US7560549B2 (en) * 2004-02-25 2009-07-14 Sankyo Company, Limited Sulfonyloxy derivatives
KR20060127157A (ko) 2004-02-25 2006-12-11 상꾜 가부시키가이샤 인다놀 유도체
RU2388751C2 (ru) 2004-07-15 2010-05-10 Амр Текнолоджи, Инк. Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
FR2873373B1 (fr) * 2004-07-23 2006-09-08 Sanofi Synthelabo Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique
WO2006023852A2 (en) * 2004-08-19 2006-03-02 Vertex Pharmaceuticals, Incorporated Modulators of muscarinic receptors
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
KR101589551B1 (ko) 2005-07-15 2016-02-02 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
NZ566180A (en) 2005-07-29 2011-04-29 Resverlogix Corp Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
CL2008000046A1 (es) 2007-01-10 2008-05-09 Angeletti P Ist Richerche Bio Compuestos derivados de 2-(4-piperidin-3-il-fenil)-7-amido-2,7a-dihidro-1h-indazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar o prevenir el cancer, enfermedades inflamatorias, lesiones por reperfusion, afeccione
EP2120555A1 (en) * 2007-01-31 2009-11-25 Adam Heller Methods and compositions for the treatment of pain
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
JP5501227B2 (ja) 2007-06-27 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
DK2346837T3 (en) 2008-06-26 2015-04-20 Resverlogix Corp Methods for preparing quinazolinone derivatives
CA2747417C (en) 2009-01-08 2017-01-03 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
NZ755378A (en) 2009-03-18 2022-07-29 Resverlogix Corp Novel quinazolinones and related compounds for use as anti-inflammatory agents
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
PT2421533T (pt) 2009-04-22 2019-01-21 Resverlogix Corp Novos agentes anti-inflamatórios
ES2528404T3 (es) 2009-05-12 2015-02-10 Bristol-Myers Squibb Company Formas cristalinas de (S)-7-([1,2,4]triazol[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y sus usos
SG175420A1 (en) 2009-05-12 2011-12-29 Albany Molecular Res Inc 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
MX2011011901A (es) 2009-05-12 2012-01-20 Albany Molecular Res Inc Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas.
AU2010307198C9 (en) 2009-10-14 2014-02-13 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
SI2606134T1 (sl) 2010-08-17 2019-08-30 Sirna Therapeutics, Inc. RNA-INTERFERENČNO POSREDOVANO ZAVIRANJE IZRAŽANJA GENA VIRUSA HEPATITISA B (HBV) Z UPORABO KRATKE INTERFERENČNE NUKLEINSKE KISLINE (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
AU2012245971A1 (en) 2011-04-21 2013-10-17 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
HUE044986T2 (hu) 2011-11-01 2019-11-28 Resverlogix Corp Orális, azonnali felszabadulású készítmények szubsztituált kinazolinonokhoz
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
BR102012024778A2 (pt) * 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
EP2925888B1 (en) 2012-11-28 2017-10-25 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
KR20150096794A (ko) 2012-12-21 2015-08-25 제니쓰 에피제네틱스 코포레이션 브로모도메인 저해제로서의 신규한 헤테로사이클릭 화합물
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3706747A4 (en) 2017-11-08 2021-08-04 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
CN113194948A (zh) * 2018-11-15 2021-07-30 国立大学法人九州大学 Il-31介导性疾病的预防或治疗剂及医药组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE903957A1 (en) * 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical preparations containing them
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2676054B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
GB9125515D0 (en) * 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
AU662943B2 (en) 1991-12-18 1995-09-21 Biosearch Italia S.P.A. 7'-amino-naphthazarin antibiotic derivatives
US5869496A (en) 1993-01-28 1999-02-09 Merck & Co., Inc. Spiro-substituted azacycles as tachykinin receptor antagonists
WO1994026735A1 (en) 1993-05-06 1994-11-24 Merrell Dow Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines useful as tachykinin antagonists
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
CA2163995A1 (en) 1993-06-07 1994-12-22 Malcolm Maccoss Spiro-substituted azacycles as neurokinin antagonists
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
WO1995028389A1 (fr) 1994-04-15 1995-10-26 Yamanouchi Pharmaceutical Co., Ltd. Compose spiro et composition medicinale issue de ce compose
FR2729951B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2729954B1 (fr) * 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2729952B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
RU2135494C1 (ru) * 1995-12-01 1999-08-27 Санкио Компани Лимитед Гетероциклические соединения и композиция на их основе, проявляющая антагонистическое действие в отношении рецепторов тахикинина
JP3192631B2 (ja) * 1997-05-28 2001-07-30 三共株式会社 飽和複素環化合物からなる医薬

Also Published As

Publication number Publication date
EP0776893A1 (en) 1997-06-04
CN1142932C (zh) 2004-03-24
IL119729A0 (en) 1997-03-18
DE69619479D1 (de) 2002-04-04
DE69619479T2 (de) 2002-10-17
AU719158B2 (en) 2000-05-04
CA2191815C (en) 2005-05-10
US6159967A (en) 2000-12-12
AU7406596A (en) 1997-06-05
IL119729A (en) 2001-07-24
NO308300B1 (no) 2000-08-28
ATE213738T1 (de) 2002-03-15
RU2135494C1 (ru) 1999-08-27
EP0776893B1 (en) 2002-02-27
PT776893E (pt) 2002-06-28
CN1157286A (zh) 1997-08-20
TW367327B (en) 1999-08-21
HU224225B1 (hu) 2005-06-28
ES2170211T3 (es) 2002-08-01
DK0776893T3 (da) 2002-03-18
CZ352196A3 (en) 1997-06-11
US6448247B1 (en) 2002-09-10
HUP9603298A2 (hu) 1998-09-28
MX9606082A (es) 1998-08-30
NO965125D0 (no) 1996-12-02
CA2191815A1 (en) 1997-06-02
NZ299859A (en) 1997-11-24
CZ288498B6 (en) 2001-06-13
HK1011366A1 (en) 1999-07-09
HU9603298D0 (en) 1997-01-28
HUP9603298A3 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
NO965125L (no) Heterosykliske forbindelser med tachykininreseptor-antagonistaktivitet, deres fremstilling og anvendelse
NO974686D0 (no) Nye substituerte piperazinderivater med tachykinin reseptor antagonist aktivitet
DE69127791D1 (de) Diazabicyclononyl-Derivate als 5-HT3 Rezeptor Antagonisten
NO20020823D0 (no) Heterosykliske forbindelser og deres anvendelse som metabotrofisk glutamatreseptor-antagonister
NO996178L (no) 4-aminopyrrol(3,2-d)pyrimidiner som neuropeptid y- reseptorantagonister
EA200100058A1 (ru) 4-бензилпиперидиналкилсульфоксидные гетероциклические соединения и их применение в качестве подтип-избирательных антагонистов nmda-рецепторов
ATE219077T1 (de) Endothelin antagoniste
DK1129091T3 (da) Antagonister for CRF-receptorer og fremgangsmåder med relation dertil
NO963731L (no) Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister
TR200000025T2 (tr) Azetidinilpropilpiperidin türevleri, ara bağlarıyla tacikinin antagonistleri olarak kullanımları.
ATE237612T1 (de) Benzofuranderivate
DK1129096T3 (da) CRF-receptorantagonister og fremgangsmåder, der er relateret dertil
ATE119524T1 (de) Substituierte n-(imidazolyl)alkyl-alanin- derivate.
GB8904551D0 (en) Chemical compounds
AU1667500A (en) N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthal necarboxamides and their use as neurokinin 1 (nk1) and/or neurokinin 2 (nk2) receptor antagonists
TR200000786T2 (tr) Vitronektin reseptör antagonisti
TR200101654T2 (tr) Vitronektin resept”r antagonistleri
DE69812010D1 (de) 4-Aminopyrrole (3,2-d) Pyrimidinen als Antagonisten des Neuropeptide Y Receptors
DK0815105T3 (da) Heterocyklisk substituerede piperazinonderivater som tachykininreceptor-antagonister
DK0712406T3 (da) Kondenserende indolderivater som 5-HT4-receptorantagonister
DE69617010D1 (de) Isazole derivate als fibrinogen-rezeptor-antagonisten
FI943872A (fi) 2,6-metano-2H-kinditsiinijohdannainen 5-HT3-reseptoriantagonistina
NO931679D0 (no) Nye heterocykliske forbindelser som antagonister for eksitatoriske aminosyrereseptorer, fremgangsmaater for deres fremstilling og deres anvendelse
ATE319452T1 (de) Arzneimittel gegen essstörungen
TR199801735A2 (xx) 2-(arilfenil)amino-imidazolin türevleri.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees